CRMD
CorMedixBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that Q1 proved CorMedix can pair commercial execution with meaningful profitability: $127.4 million of Q1 net revenue, $38.6 million of net income, $70.0 million of adjusted EBITDA, higher 2026 guidance, and REZZAYO prophylaxis progress together support a multi-leg growth narrative [#SEC-8K-2026-05-14].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Coverage is sparse, limiting outside validation of post-earnings estimate revisions, target changes, and downside scenarios.
Momentum
28
Value
72
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.50 · Bull $13.00 · Bear $6.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $15.00
Why
Momentum28 · Δ7d -11.5
Value72 · Δ7d -0.2
Sentiment67 · Δ7d -16.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
28
26% active weight
Current posture
7d trendFlat
Δ7d
-11.5
Δ21d
-37.5
Value
72
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.0
Sentiment
67
34% active weight
Current posture
7d trendSoftening
Δ7d
-16.6
Δ21d
-15.6
Why this grade
Composite grade B. Momentum 27.5 / Value 71.7 / Sentiment 67.3
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$660.57M
Beta
1.40
Shares Out
78.45M
P/E (TTM)
5.9
P/S (TTM)
4.48
P/FCF (TTM)
12.91
Rev YoY
+226.1%
EPS YoY
+38.7%
Gross Margin
+85.8%
Op Margin
+48.5%
Net Debt
-$273K
Current Ratio
2.98
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology